About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a Healthcare company (Biotechnology) with a market capitalization of $30.1B. Its Maz Rating is 3.98 out of 5 (B+, Buy), ranked against the other companies in its sector.

Factor scores: Valuation 2.10, Growth 4.78, Profitability 4.66, Financial Health 4.07, Momentum 2.50 (as of 2026-10-16).

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

CEO

Yvonne L. Greenstreet

Employees

2,500

IPO date

2004-06-01